News

 

NEWS

Neopeutics Wins 2015 North America Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as […]

Read more

Symic Adds Expertise to its Board

Symic Biomedical announced today the appointment of Barbara Yanni and William J. Newell to its board of directors. Mr. Newell is the CEO of Sutro Biopharma, Inc. which has entered into a strategic collaboration and acquisition option with Celgene regarding their therapeutic technology platform. Ms. Yanni retired in 2014 from Merck & Co., Inc. where she was most recently Vice […]

Read more

Amarantus to Present Positive Alzheimer’s Disease Biomarker Data

Amarantus announced that its abstract titled “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” was accepted for poster presentation at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.  Read the press release at […]

Read more

MedGenome to Raise $15M in Second Round of Funding

MedGenome, backed by Mu Sigma co-founders Dhiraj Rajaram and Ambiga Dhiraj, is looking to raise $15 million in a second round of funding to set up additional genome test labs. The clinical research and diagnostics firm is seeking a valuation of more than $100 million, a near ten-fold jump from last year, when it raised $4 million in its first […]

Read more

Amarantus Inks Alzheimer’s Biomarker Test Deal with Anavex

Amarantus BioScience Holdings today said that it has signed a deal to provide biomarker test services to Anavex Life Sciences for studies of that firm’s Alzheimer’s drug candidate. Under the deal, Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69 in specific sub-populations of peripheral […]

Read more

Senior Management Changes at Assembly Biosciences

Co-founder Derek Small succeeds Russell H. Ellison, MD, as CEO, as had been agreed in the merger last year that established Assembly. Small remains President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. Read the press release at Globe […]

Read more

John Mulcahy, SiteOne Therapeutics

Developing a non-addictive painkiller to compete with opiates Mission Bay Capital portfolio company John Mulcahy is co-founder and vice-president of research at SiteOne Therapeutics, a company developing a non-addictive oral replacement for narcotic pain medications such as oxycodone and Vicodin. SiteOne recently won a $1.4M SBIR grant and raised $1.5M in private funding, including an investment by QB3’s fund Mission […]

Read more

Colleen Cutcliffe, Whole Biome

Improving human health by sequencing and analyzing the microbiome and developing targeted therapies Colleen Cutcliffe is co-founder and CEO of Whole Biome, a company working with the Mayo Clinic and others to analyze the microbiome—the community of microorganisms that lives on and in our bodies—and to develop therapies that use the microbiome to improve human health. Whole Biome, which has […]

Read more

Uri Lopatin, Assembly Biosciences

Targeting the hepatitis B virus Ramen to reverse merger in under two years. Uri Lopatin co-founded Assembly Pharmaceuticals in 2012, first working from home and then riding his bicycle to our incubator. At one point he literally ate ramen noodles for two months straight. But less than two years later, his startup merged with Ventrus Biosciences to form Assembly Biosciences, […]

Read more

MedGenome keen to team-up with state govts

MedGenome is looking to partner with the state governments in the country to offer its OncoMD, a cancer analytics platform with information on over 1.2 million cancer mutations allowing accurate interpretation of genomic variations. Currently in India there are cancer camps conducted in rural areas and district hospitals. In Karnataka the state government owned Kidwai Memorial Institute of Oncology has […]

Read more
Page 9 of 10« First...678910

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    09:00-11:00
    03/01/2018
    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter